IRON vs VCEL
IRON: Disc Medicine is a clinical-stage biopharmaceutical firm advancing a pipeline of novel therapies to treat serious hematologic and red blood cell disorders by targeting heme biosynthesis and iron homeostasis. VCEL: Vericel is a commercial-stage biotechnology company that develops and markets autologous cell therapies for the treatment of severe burns and cartilage damage in the knee.
Side-by-side fundamentals
| Metric | IRON | VCEL | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $74.61 | $45.32 | |
| Market cap as of 2026-08-03 | $2.9B | $2.3B | |
| P/E as of 2026-08-03 | n/a | 109.36 | |
| PEG as of 2026-08-03 | -0.26 | 0.38 | IRON lower |
| Net margin as of 2026-08-03 | n/a | +7.3% | |
| Gross margin as of 2026-08-03 | n/a | +74.8% | |
| Operating margin as of 2026-08-03 | n/a | +5.4% | |
| ROE as of 2026-08-03 | -37.2% | +6.4% | VCEL higher |
| ROA as of 2026-08-03 | -33.7% | +4.6% | VCEL higher |
| Debt / equity as of 2026-08-03 | 0.09 | 0.00 | VCEL lower |
| Revenue growth (YoY) as of 2026-08-03 | n/a | +22.4% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +18.9% | |
| Beta as of 2026-08-03 | 0.97 | 1.07 | |
| 1-year return as of 2026-07-27 close | +23.1% | +13.0% | IRON higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.